Abbott's XIENCE Stent Receives FDA Approval for Shortest Blood Thinner Course for High Bleeding Risk Patients
In addition, XIENCE stents recently received CE Mark approval for DAPT as short as 28 days giving XIENCE stents the shortest DAPT indication in the world.
- In addition, XIENCE stents recently received CE Mark approval for DAPT as short as 28 days giving XIENCE stents the shortest DAPT indication in the world.
- In addition to the HBR indication, Abbott has also received FDA approval and European CE Mark approval for its next-generation XIENCE Skypoint stent.
- "The new FDA approval for DAPT for the XIENCE family of stents provides interventional cardiologists confidence they are delivering the best care to patients with high bleeding risk.
- With the shortest approved DAPT labeling, Abbott's XIENCE stents can help physicians treat their HBR patients more effectively.